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Chapter 3. EED Library as a Basis for 
Systematic Reviews 
3.1 Defining Systematic Review Question Priorities 
Evidence related to any topic area and addressing questions raised in Table 2 has 
potential to move the EED field forward. While an argument could be made to pursue any of the 
topic areas/questions, we had to define a starting question to address and had to develop a 
prioritization scheme given the importance of many of the topic areas/questions. Descriptive 
epidemiology (topic area I in Table 2), for example, would certainly be useful to gauge the scope 
of the problem, but would probably not produce useful recommendations. We considered 
developing a review that considered EED as a dependent variable (i.e., an outcome) of 
processes and risk factors (topic area II in Table 2). Such a characterization might be used to 
develop preventive interventions for EED. We next formulated a model of EED as an event that 
causes many injuries in the host (topic area III in Table 2), such as stunting and micronutrient 
deficiencies. A review based on this model could be considered an analysis of its consequences 
by focusing on host injuries and population impact. Biomarkers of EED as a subject for review 
(topic area IV in Table 2) could provide a compendium of tools that could be used to detect 
EED, and possibly to shed light on its origin. Consideration was additionally given to reporting 
the clinical course and pathophysiology of EED (topic area V in Table 2), to summarize the state 
of knowledge about cellular and organ processes that underlie its disease course. Finally, we 
considered reviewing existing treatment or prevention interventions for EED (topic area VI in 
Table 2).  
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To provide direction for our initial efforts, we decided that it was important to select areas 
in which a sufficient body of data is likely to exist. An additional attribute for a useful review is 
that the resulting analysis can be used for disease control.  
With these considerations in mind, we narrowed the set to four lead questions:  
1. What is the evidence that EED is caused by (an) identifiable pathogen(s), 
microbial populations, environmental or other identifiable factors? 
2. What is the evidence that EED can be prevented by any interventions? 
3. What is the evidence that EED can be noninvasively diagnosed? 
4. What is the evidence regarding efficacy/effectiveness of treatment 
interventions for EED? 
Based on deliberations amongst the co-authors, and engagement with the Bill & Melinda 
Gates Foundation, as well as discussions at the Gut Integrity Workshop held in Seattle, 
Washington in December 2010, we focused on noninvasive diagnosis of EED as a priority 
systematic review question. 
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3.2 Determining Relevance to the Systematic 
Review 
We carefully considered the specifics of the review question and framed the question for 
consistency with the Population Intervention Comparison Outcome (PICO) framework for 
systematic review questions [99]: 
What biomarkers or diagnostic tests1 have been used to identify or have been shown to 
be associated with mucosal dysfunction of the small intestine2 or host inflammation3 in 
children under five years of age from developing-country settings4? 
For the purpose of this systematic review question, dysfunction was defined as 
manifestation of increased small intestinal permeability, decreased absorption of nutrients, 
enteric inflammation, or abnormal enterocyte metabolism or cell function. These conditions 
could be present in children with environmental enteric dysfunction based on histology or 
persistent diarrhea or those with malnutrition, or who were clinically asymptomatic. Evaluation of 
asymptomatic or “normal” subjects without overt clinical evidence of enteric dysfunction or those 
with acute diarrhea was of interest as long as they were evaluated for tests of mucosal small 
intestinal dysfunction (e.g., endoscopy, histology, or markers of permeability or absorption from 
serum, urine, or stool) or they were being tested in the same study as children with persistent 
diarrhea. Gastrointestinal dysfunction or enteropathy related to celiac disease, cow's milk 
protein allergy (CMPA), inflammatory bowel disease, or cystic fibrosis, as well as primary 
                                                     
1 Assessments of host biological materials or imaging assessments (e.g. radiologic) of the host. 
2 Including increased small intestinal permeability, decreased absorption of nutrients, enteric 
inflammation, or abnormal enterocyte metabolism or cell function among those with enteropathy (e.g. 
environmental enteric dysfunction (EED) based on histology or persistent diarrhea) or children with 
malnutrition or clinically asymptomatic children.  
3 Laboratory confirmed generalized or tissue inflammation, but not necessarily specifically measuring gut-
specific inflammation, e.g. C-reactive protein (CRP), IL-6. 
4 Defined as low or middle income country as determined by World Bank or among marginalized or 
indigenous populations in a developed country. 
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immunodeficiency disorders (e.g., X-linked agammaglobulinemia, common variable 
immunodeficiency, IgA deficiency, IgG subclass deficiency) were excluded from this systematic 
review.  
Studies that used tests or markers specifically related to small intestinal mucosal 
function (except for the aforementioned excluded specific enteropathies) among children under 
five years of age from a developing country setting were included. These tests include biopsy, 
tests of nutrient absorption (e.g., iron absorption), tests of gut permeability and/or absorption 
(e.g., D-xylose, lactulose:mannitol ratio [L:M]), and stool markers (e.g., fecal fat, reducing 
substances). Articles describing tests or markers of systemic inflammation that can be affected 
by mucosal intestinal function (e.g., IL-6, C-reactive protein (CRP), blood counts) were also 
included as long as they were conducted: a) among children with EED or enteric dysfunction 
consistent with EED (e.g., those with persistent diarrhea and without an excluded enteropathy), 
b) among acute diarrhea or asymptomatic patients in a study that compared results to subjects 
with a small intestinal mucosal disorder of interest, or c) in association with a test of mucosal 
small intestinal function. Articles that were limited to tests of micronutrient status, celiac or 
CMPA disease-specific tests, or tests for specific pathogens were excluded from the systematic 
review.  
We decided to restrict this analysis to articles published between 2000 and 2010 in the 
interest of producing an expedited analysis of a well-defined literature set. We retain the ability 
to apply this methodology to the literature identified for prior intervals. We also performed an 
assessment of 10 references chosen at random that were published between 1990 and 1999 to 
determine the scope of additional information that an analysis of the literature prior to our 
restricted time block might provide (Appendix 3). Of the 10 articles, only one had a sample size 
of 100 or more subjects under five years of age. Overall, these articles do not lend substantial or 
novel data to content already derived from the 2000-2010 analysis. 
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We acknowledge that delving back to prior decades could provide additional informative 
data. This is especially true because much study regarding EED occurred in the 1970s and 
1980s and waned in the subsequent decades, and because technology is not evolving rapidly in 
this field. However, secular trends in socioeconomic, environmental, nutritional, and disease 
conditions as well as improvements in laboratory, epidemiologic, and biostatical methods 
complicate comparison of data across studies from different time periods. Also, earlier studies 
focused on adults. 
The team included analysts knowledgeable in German, French, Spanish, Italian, and 
Portuguese; thus, we were able to thoroughly dissect articles in these languages. References in 
other languages were excluded as we were not able to translate other languages in detail 
sufficient for the purposes of thorough extraction and analysis.  
A summary of inclusion/exclusion criteria and of the instructions given to analysts is 
provided in Table 6. 
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Table 6. Guidelines for systematic review inclusion/exclusion determination and data 
extraction.  
Biomarkers and Diagnostics Systematic Review Question: 
What biomarkers or diagnostic tests1 have been used to identify or have been shown to be 
associated with mucosal dysfunction2 of the small intestine or host inflammation3 in children 
under five years of age from developing-country settings4? 
1 Assessments of host biological materials or imaging (e.g., radiologic) assessments of the host.  
2 Dysfunction can be related to increased small intestinal permeability, decreased absorption of 
nutrients, enteric inflammation, or abnormal enterocyte metabolism or cell function among those 
with enteropathy (e.g., EED based on histology, persistent diarrhea) or children with malnutrition 
or clinically asymptomatic children.  
3 Laboratory-confirmed generalized or tissue inflammation, but not necessarily specifically 
measuring gut-specific inflammation (e.g. CRP, IL-6). 
4 Developing-country setting is defined as a low- or middle-income country (as classified by 
World Bank) or among indigenous populations in a developed country. 
 
Excludable conditions (non-EED enteropathies) 
Celiac disease, IBD, CMPA, cystic fibrosis (CF) (diagnosed by abnormal sweat test), as well as 
primary immunodeficiency disorders (e.g., X-Linked agammaglobulinemia, common variable 
immunodeficiency, IgA deficiency, IgG subclass deficiency) were not conditions of interest for 
this review unless the following circumstances existed:  
1. The study had controls or other subjects of interest who underwent diagnostic tests that 
are of interest to us (see "Category I Tests," below). 
2. The condition (i.e., celiac disease, CMPA, IBD) did not meet our systematic review 
criteria for defining or diagnosing that condition. In other words, these disorders may have been 
incorrectly diagnosed and could actually have been an enteric dysfunction of interest.  
 
Asymptomatic children and children with acute diarrhea:  
 
Evaluation of asymptomatic or ‘normal’ subjects without overt clinical evidence of enteropathy or 
those with acute diarrhea was pertinent to our review as long as the included tests of mucosal 
small intestinal dysfunction (e.g., endoscopy, histology, or serum, urine, or stool markers of 
permeability or absorption). We were not interested in asymptomatic children or those with 
acute diarrhea if tested for only systemic markers, unless they were tested in the same study as 
children with EED or persistent diarrhea (PD). We were interested in the comparison of 
systemic tests in patients who are asymptomatic and/or have acute diarrhea vs. PD. For 
example, if a systemic marker was measured in subjects who were asymptomatic or had acute 
diarrhea, we did not include these data. However, if these tests were also performed in a PD 
group, then we included the data from all of these subjects— acute diarrhea, PD, and 
asymptomatic subjects— taking care to separate findings by these categories.  
We did not include references about children who presented with abdominal pain, vomiting, 
anemia, rectal bleeding, gastroesophageal reflux, etc., unless they reported to have also had 
EED, tropical enteropathy (TE), environmental enteropathy (EE), PD, malabsorption, or other 
symptoms suggesting small intestinal mucosal dysfunction.  
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Tests to Include: 
Tests specific to intestinal dysfunction: We included biomarkers and diagnostic tests specifically 
related to small intestinal mucosal function if other inclusion criteria were met (i.e., age under 5, 
developing-country setting, etc.). We included these types of tests:  
• Endoscopy 
• Intestinal biopsy or lavage 
• Lactose/sucrose load test 
Tests of nutrient absorption (not static blood levels; see Excludable Diagnostic Tests, below), 
such as the following: 
• B12 absorption 
• Iron absorption 
• Calcium absorption 
• 13C sucrose or hydrogen breath test (HBT) 
Urine markers of gut permeability or absorption: 
• D-xylose 
• Creatinine, fraction excretion 
• Lactulose, fraction excretion 
• Sucrose, fraction excretion 
• Sucralose, fraction excretion 
• Mannitol, fraction excretion 
• L:M (lactulose:mannitol) ratio 
• Sucrose:lactulose ratio 
• Sucralose:lactulose ratio 
• Urea:creatinine ratio 
• Lactose:creatinine ratio 
Any stool markers (except those testing for specific micro-organisms; see Excludable Diagnostic 
Tests, below), such as the following:  
• Alpha-1-antitrypsin 
• Calprotectin 





• Reducing substances 
• Leukocytes (i.e., white blood cells (WBCs) by microscopy 
• Occult blood testing (including guiac) 
• Red blood cells (RBCs) by microscopy 
Systemic, Non-specific Tests: Many biomarkers and diagnostic tests, including the below list of 
systemic markers of inflammation, can be impacted by mucosal intestinal function, but they can 
also be impacted by other non-gastrointestinal disorders.  
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For these tests, we only included if one or more of the following conditions were met: 
1. They were conducted among patients with a mucosal small intestinal disorder of interest 
(e.g., EED, PD, or among asymptomatic or acute diarrhea subjects in a study that also 
examined subjects with mucosal small intestinal disorder of interest).   
2. The tests were reported in relation to a test of mucosal small intestinal function (see list 
above).  
Examples of systemic, non-specific tests are the following: 
• Hemoglobin (HGB), hematocrit (HCT) (blood cell counts) 
• Total serum proteins and other serum proteins such as albumin, pre-albumin 
• Serum lipids and lipoproteins 
• Liver function tests (e.g., alanine transaminase) 
• Urine sodium (Na) 
• Urine pH 
• Systemic inflammatory markers such as: 
• C-reactive protein (CRP) 
• Erythrocyte sedimentation rate (ESR) 
• Tumor necrosis factor (TNF) 
• Interleukin-6 (IL-6) 
• Interferon-gamma (IFN-gamma) 
• Alpha-1-acid glycoprotein (AGP) 
• Serum immunoglobulins 
• Immune cell subsets 
• Ferritin 
Algorithm for our inclusion/exclusion decisions on tests/markers: 
1?? Was the test performed on children under five years in a developing-country setting? If 
no, exclude. If yes, continue. 
2. Is the test on the list of excludable tests? If yes, exclude. If no, continue. 
3. Is the test potentially related to small intestinal mucosal function? If no, exclude. If yes, 
continue. 
4. Is the test specific for small intestinal mucosal function? If yes, include and extract data. 
If no, continue. 
5. Is the test a more general test that could be related to dysfunction of other organ 
systems? If no, exclude. If yes, continue. 
6. Was the test assessed among children with mucosal small intestinal dysfunction or 
among children who have been assessed for mucosal small intestinal dysfunction? If no, 




 3.3 Acquisition of References and Copyright Fair 
Use Compliance 
References potentially relevant to the systematic review were determined by querying 
the EED Library Access database. The query identified references tagged as explicitly EED-
related and relevant to or possibly relevant to topic area IV (i.e., diagnostic tests and 
biomarkers).  
Starting in reverse chronological order, full texts of references that were identified as 
potentially relevant to the systematic review were obtained as Portable Document Format files 
(PDFs) and deposited into a central repository on Google Drive. 
We maintained compliance with Fair Use obligations of U.S. Copyright Law, 
watermarking all PDFs and making the Google Drive repository available only to team 
members. Furthermore, analysts who performed data extraction indicated their compliance with 
fair use when logging into the data entry system, via a checkbox that stated “I agree to use this 
article according to US copyright law.”  
3.4 Documenting Relevance to the Systematic 
Review 
Two principal investigators (DMD, PIT) and/or lead analysts (ZCN, KMV) reviewed 
discordant decisions made by research analysts (RAs) to determine relevance of references to 
the systematic review according to written guidelines (Table 6). In addition, a subset of 
concordant decisions (with an emphasis on excluded references) was reviewed for quality 
control.  
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 After the systematic search of the EED Library, we employed the "snowball technique" to 
identify further articles relevant to the systematic review. The snowball technique involves 
review of bibliographies of references determined as relevant to the systematic review, and 
cited articles were cross-checked against the EED Library. If not already included in the Library, 
the article was evaluated for inclusion in the Library and the systematic review. 
3.5 Data Extraction for the Systematic Review 
For data extraction, presentation, and analysis, we utilized the REDCap (Research 
Electronic Data Capture) system (http://project-redcap.org/). REDCap is a secure, web-based 
application for construction and management of online surveys and databases from multiple 
users [100]. A sample REDCap template for data extracted from systematic review references 
can be found in Appendix 4. 
After inclusion/exclusion decisions for the review were finalized, six analysts extracted 
data from studies into REDCap. The analysts were provided written guidelines on the type of 
data to be extracted (Table 6). Conference call training sessions were employed to reinforce 
guidelines and to address questions. Analysts were instructed to extract data on relevant facets 
including: study objectives, outcome of relevance to review question, setting, study design, 
subject description, case definition for subjects of interest, age groups and age range, study 
population, sample size for review question, biomarkers or diagnostic tests, test conditions and 
specifications, and results, as well as provide their impression of the evidence quality and a 
study synopsis. Extracted data were reviewed for accuracy and completeness by lead analysts, 
who made edits as needed and provided feedback to the RAs to increase efficiency and 
accuracy.  
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 We exported specific fields of data from REDCap, facilitating analyses and data 
presentation in evidence table format. From these characterizations, we portrayed the spectrum 
of responses in quantitative and free-text formats as needed. 
It is important to note that the EED Library, with references from PubMed, EMBASE, 
Global Health, and WHO Regional databases that were published between 1980 and 2010, 
remains available for research relevant to enteric dysfunction in children in resource-poor 
environments.  
3.6 EED Library: Search Results Overview 
The systematic search of PubMed, Embase, WHO Regional, and Global Health 
databases yielded 85,334 references of potential relevance to the EED Library. 17,431 
references that were published before 1980 have not been assessed for inclusion in the Library. 
67,903 references published between 1980 and 2010 are depicted in Figure 6. A small portion 
of this set was not reviewed because full text was necessary for determination, but was not 
available (i.e., we were unable to retrieve 89 articles published between 2000 and 2010). 
66,541 references were dual-reviewed against EED Library inclusion criteria with 9,669 
admitted to the project Library. Fifteen percent of those included were reviews, commentaries, 
abstract proceedings, books, or editorials, and the remainder were references with primary data. 
To conserve project resources, approximately 1,350 articles from the original systematic search 
that were published before 2000 were not reviewed for library inclusion.  
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 Figure 6. Flowchart of project procedure results. 
 
3.7 Quality Control 
Accuracy and completeness in coding inclusion/exclusion and labels, tags, and topic 
areas by analysts were closely monitored. Means for the percent of inaccurate exclusion and 
inclusion and for kappa statistics were weighted based on the number of reference 
spreadsheets reviewed by each analyst. The overall inaccurate exclusion and inclusion rates 
were 2.2% and 2.7%, respectively. The kappa average for the group of analysts was 0.76, 
which is considered to be in the "substantial concordance" range [98]. In addition, 1,200 
references that were concordantly excluded by two analysts were reviewed by a lead analyst; 
the exclusion error rate for these references was 0.5% (Table 7).  
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 Table 7. Accuracy rates for inclusion and exclusion. 
Concordance/discordance between analysts and study investigators on an evaluation set of 















     
A 5.2 3.4 0.46 1800 
B 0.9 3.2 0.83 11400 
C 2.9 0.9 0.78 2000 
D 1.9 2.9 0.78 7800 
E 2.9 1.3 0.74 6400 
F 5.8 6.4 0.50 600 
G 6.4 3.7 0.61 200 
H 2.9 3.3 0.75 600 
I 4.2 6.5 0.67 800 
J 3.3 0.7 0.79 600 

















 2.2 2.7 0.76 0.5 % 
 
3.8 EED Library Status 
Twenty percent of all of the references derived from our initial systematic search of the 
PubMed, Embase, and Global Health databases were published between 2006 and 2010. The 
discordance between the abundance of references that we found in our search and the paucity 
of references found in the ISI query suggest that relevant literature is indexed with search terms 
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 that are neither sensitive nor specific. The inclusive approach using terms that broadened the 
scope of papers identified was therefore warranted, even though such broadening obligated the 
inclusion of over 85,000 references.  
Furthermore, careful documentation of our search terms allows reproducibility despite 
the complex nature of our strategy. The search strategy can be replicated and resultant 
references run through our project procedures to update the Library at any time. In addition, the 
search strategy designed for this project can be modified if related searches are needed.  
The EED Library, as derived from PubMed, EMBASE, Global Health and WHO Regional 
databases and published between 1980 and 2010, was designed to be a resource for scientists, 
public health and clinical practitioners working on a variety of EED investigations. In fact, we 
have interrogated our EED Library for several groups of researchers in the field:  
1. Dr. David Rudnick at Washington University in St. Louis requested assistance in 
his work on liver function and growth in resource-limited settings, and we queried 
the database as regards the role of aflatoxin and growth as reflected in the 
literature.  
2. We provided a list of references from the last decade that reported use of 
biopsies among children in resource-limited settings to Dr. James Lavery‘s team 
in Toronto to assist in their examination of ethical considerations of invasive and 
noninvasive assessments of what they termed "tropical enteropathy/enteric 
enteropathy." 
3. We provided data from our database to Dr. Gerald Keusch’s team (which 
includes co-authors Drs. Denno and Tarr) who were building a working definition 
of EED.  
4. The master evidence table was made available to all of the participants of the Bill 
and Melinda Gates Foundation Grand Challenges Gut Function Biomarker 
Shaping Meeting in London in June 2012. 
5. We performed a pilot project for the Bill and Melinda Gates Foundation to 
determine the number of studies in the EED database that involved interventions. 
We further determined how many of these were clinical trials vs. treatment 
studies, categorized the interventions, and tallied the number of studies per 
category. 
The EED Library can be searched using the codes, labels and tags that our Research 
Analyst team assigned to EED Library records. Continued assembly of literature post-2010 
would add value if the database is to be further utilized to address other queries. 
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